EGFR and head and neck squamous cell carcinoma: In summary, our results introduce ANO1 expression as a predictive biomarker for the response to EGFR-targeting therapy in HNSCC and suggest combination of anti-EGFR and anti-ANO1 directed therapies as a promising therapeutic strategy for the treatment of HNSCC.